Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 4
1959 5
1960 40
1961 70
1962 90
1963 132
1964 134
1965 70
1966 60
1967 67
1968 79
1969 107
1970 107
1971 117
1972 130
1973 152
1974 145
1975 125
1976 142
1977 142
1978 122
1979 124
1980 112
1981 115
1982 90
1983 101
1984 122
1985 89
1986 92
1987 91
1988 94
1989 74
1990 92
1991 80
1992 85
1993 77
1994 103
1995 68
1996 68
1997 83
1998 92
1999 98
2000 157
2001 165
2002 197
2003 263
2004 238
2005 310
2006 275
2007 252
2008 239
2009 279
2010 286
2011 289
2012 327
2013 337
2014 295
2015 297
2016 342
2017 299
2018 305
2019 311
2020 332
2021 332
2022 159
Text availability
Article attribute
Article type
Publication date

Search Results

9,620 results
Results by year
Filters applied: . Clear all
Page 1
Spironolactone.
Carone L, Oxberry SG, Twycross R, Charlesworth S, Mihalyo M, Wilcock A. Carone L, et al. J Pain Symptom Manage. 2017 Feb;53(2):288-292. doi: 10.1016/j.jpainsymman.2016.12.320. Epub 2016 Dec 23. J Pain Symptom Manage. 2017. PMID: 28024992 Free article. Review.
A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Struthers A, Krum H, Williams GH. Struthers A, et al. Clin Cardiol. 2008 Apr;31(4):153-8. doi: 10.1002/clc.20324. Clin Cardiol. 2008. PMID: 18404673 Free PMC article. Review.
This article reviews the pharmacology, clinical efficacy, and tolerability of the two available blocking agents, spironolactone and eplerenone. A Medline search identified clinical studies assessing spironolactone and eplerenone. Priority was given to large, well-co …
This article reviews the pharmacology, clinical efficacy, and tolerability of the two available blocking agents, spironolactone and e …
Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C. Lainscak M, et al. Int J Cardiol. 2015 Dec 1;200:25-9. doi: 10.1016/j.ijcard.2015.05.127. Epub 2015 May 21. Int J Cardiol. 2015. PMID: 26404748 Review.
From a marginal role as a potassium-sparing diuretic, spironolactone has been shown to be an extraordinarily effective adjunctive agent in the treatment of progressive heart failure. Also, spironolactone is safe and protective in arterial hypertension, particularly …
From a marginal role as a potassium-sparing diuretic, spironolactone has been shown to be an extraordinarily effective adjunctive age …
Spironolactone for hypertension.
Batterink J, Stabler SN, Tejani AM, Fowkes CT. Batterink J, et al. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD008169. doi: 10.1002/14651858.CD008169.pub2. Cochrane Database Syst Rev. 2010. PMID: 20687095 Review.
BACKGROUND: Spironolactone is an aldosterone antagonist, considered fourth line therapy for hypertension in patients already treated with multiple medications. OBJECTIVES: Primary: to determine the effect of spironolactone on patient mortality, morbidity, and to qua …
BACKGROUND: Spironolactone is an aldosterone antagonist, considered fourth line therapy for hypertension in patients already treated …
Spironolactone.
Ochs HR, Greenblatt DJ, Bodem G, Smith TW. Ochs HR, et al. Am Heart J. 1978 Sep;96(3):389-400. doi: 10.1016/0002-8703(78)90052-2. Am Heart J. 1978. PMID: 356569 Review. No abstract available.
Spironolactone.
[No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risk Chem Hum. 1980;24:259-73. IARC Monogr Eval Carcinog Risk Chem Hum. 1980. PMID: 7009396 Review. No abstract available.
Eplerenone.
Brown R, Quirk J, Kirkpatrick P. Brown R, et al. Nat Rev Drug Discov. 2003 Mar;2(3):177-8. doi: 10.1038/nrd1039. Nat Rev Drug Discov. 2003. PMID: 12619638 Review. No abstract available.
Antimineralocorticoids.
Agarwal MK, Lazar G. Agarwal MK, et al. Ren Physiol Biochem. 1991 Nov-Dec;14(6):217-23. doi: 10.1159/000173409. Ren Physiol Biochem. 1991. PMID: 1720252 Review.
A number of chemical modifications in the spironolactone molecule were attempted over the last decade to synthesize ligands with high affinity for the mineralocorticoid receptor (MCR), and for possible use in the clinical control of the hypertensive disease. ...None of the …
A number of chemical modifications in the spironolactone molecule were attempted over the last decade to synthesize ligands with high …
Use of spironolactone to treat acne in adolescent females.
Roberts EE, Nowsheen S, Davis DMR, Hand JL, Tollefson MM, Wetter DA. Roberts EE, et al. Pediatr Dermatol. 2021 Jan;38(1):72-76. doi: 10.1111/pde.14391. Epub 2020 Oct 3. Pediatr Dermatol. 2021. PMID: 33009838
BACKGROUND/OBJECTIVES: Studies assessing the utility of spironolactone for treating acne in adolescent females are lacking. Thus, we sought to examine spironolactone's role in treating this patient population. ...CONCLUSIONS: Spironolactone demonstrate …
BACKGROUND/OBJECTIVES: Studies assessing the utility of spironolactone for treating acne in adolescent females are lacking. Thus, we …
Spironolactone.
Danby FW. Danby FW. J Am Acad Dermatol. 1992 Jan;26(1):137. doi: 10.1016/s0190-9622(08)80534-8. J Am Acad Dermatol. 1992. PMID: 1580900 No abstract available.
9,620 results